Neos Therapeutics Inc. (NASDAQ:NEOS) was down 3.2% on Wednesday . The company traded as low as $9.06 and last traded at $9.08, with a volume of 61,077 shares trading hands. The stock had previously closed at $9.38.

A number of equities research analysts have weighed in on NEOS shares. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Thursday, April 21st. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. JMP Securities dropped their price objective on shares of Neos Therapeutics from $33.00 to $32.00 and set a “market outperform” rating for the company in a report on Wednesday, March 9th. BMO Capital Markets began coverage on shares of Neos Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Royal Bank Of Canada dropped their price objective on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Neos Therapeutics has a consensus rating of “Buy” and an average target price of $21.75.

The stock’s market capitalization is $145.69 million. The stock has a 50-day moving average price of $9.65 and a 200 day moving average price of $10.22.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Monday, May 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.08. Analysts forecast that Neos Therapeutics Inc. will post ($4.88) EPS for the current fiscal year.

In other news, insider Juergen Martens bought 10,000 shares of Neos Therapeutics stock in a transaction on Monday, June 13th. The shares were bought at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the acquisition, the insider now owns 10,000 shares in the company, valued at $99,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Presidio Partners 2007, L.P. sold 57,968 shares of the company’s stock in a transaction dated Friday, April 15th. The shares were sold at an average price of $10.23, for a total transaction of $593,012.64. Following the completion of the transaction, the insider now owns 1,623,997 shares in the company, valued at $16,613,489.31. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP boosted its position in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, Holdings Channel reports. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent filing with the SEC.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.